These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells. Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872 [TBL] [Abstract][Full Text] [Related]
7. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells. Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904 [TBL] [Abstract][Full Text] [Related]
8. RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes. Wang C; Li D; Zhang L; Jiang S; Liang J; Narita Y; Hou I; Zhong Q; Zheng Z; Xiao H; Gewurz BE; Teng M; Zhao B J Virol; 2019 Jul; 93(13):. PubMed ID: 31019051 [TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2. Portal D; Zhou H; Zhao B; Kharchenko PV; Lowry E; Wong L; Quackenbush J; Holloway D; Jiang S; Lu Y; Kieff E Proc Natl Acad Sci U S A; 2013 Nov; 110(46):18537-42. PubMed ID: 24167291 [TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A. Jiang S; Willox B; Zhou H; Holthaus AM; Wang A; Shi TT; Maruo S; Kharchenko PV; Johannsen EC; Kieff E; Zhao B Proc Natl Acad Sci U S A; 2014 Jan; 111(1):421-6. PubMed ID: 24344258 [TBL] [Abstract][Full Text] [Related]
11. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. Faumont N; Durand-Panteix S; Schlee M; Grömminger S; Schuhmacher M; Hölzel M; Laux G; Mailhammer R; Rosenwald A; Staudt LM; Bornkamm GW; Feuillard J J Virol; 2009 May; 83(10):5014-27. PubMed ID: 19264782 [TBL] [Abstract][Full Text] [Related]
12. Shared and distinct interactions of type 1 and type 2 Epstein-Barr Nuclear Antigen 2 with the human genome. Viel KCMF; Parameswaran S; Donmez OA; Forney CR; Hass MR; Yin C; Jones SH; Prosser HK; Diouf AA; Gittens OE; Edsall LE; Chen X; Rowden H; Dunn KA; Guo R; VonHandorf A; Leong MML; Ernst K; Kaufman KM; Lawson LP; Gewurz B; Zhao B; Kottyan LC; Weirauch MT BMC Genomics; 2024 Mar; 25(1):273. PubMed ID: 38475709 [TBL] [Abstract][Full Text] [Related]
13. Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9. Harth-Hertle ML; Scholz BA; Erhard F; Glaser LV; Dölken L; Zimmer R; Kempkes B PLoS Pathog; 2013 Sep; 9(9):e1003638. PubMed ID: 24068939 [TBL] [Abstract][Full Text] [Related]
14. The Epstein-Barr Virus Regulome in Lymphoblastoid Cells. Jiang S; Zhou H; Liang J; Gerdt C; Wang C; Ke L; Schmidt SCS; Narita Y; Ma Y; Wang S; Colson T; Gewurz B; Li G; Kieff E; Zhao B Cell Host Microbe; 2017 Oct; 22(4):561-573.e4. PubMed ID: 29024646 [TBL] [Abstract][Full Text] [Related]
15. EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes. Su C; Lu F; Soldan SS; Lamontagne RJ; Tang HY; Napoletani G; Farrell PJ; Tempera I; Kossenkov AV; Lieberman PM PLoS Pathog; 2021 Aug; 17(8):e1009834. PubMed ID: 34352044 [TBL] [Abstract][Full Text] [Related]
16. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions. Rowe M; Raithatha S; Shannon-Lowe C J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803 [TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway. Pegman PM; Smith SM; D'Souza BN; Loughran ST; Maier S; Kempkes B; Cahill PA; Simmons MJ; Gélinas C; Walls D J Virol; 2006 Aug; 80(16):8133-44. PubMed ID: 16873269 [TBL] [Abstract][Full Text] [Related]
18. The nuclear chaperone nucleophosmin escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells. Liu CD; Chen YL; Min YL; Zhao B; Cheng CP; Kang MS; Chiu SJ; Kieff E; Peng CW PLoS Pathog; 2012; 8(12):e1003084. PubMed ID: 23271972 [TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr Virus Episome Physically Interacts with Active Regions of the Host Genome in Lymphoblastoid Cells. Wang L; Laing J; Yan B; Zhou H; Ke L; Wang C; Narita Y; Zhang Z; Olson MR; Afzali B; Zhao B; Kazemian M J Virol; 2020 Nov; 94(24):. PubMed ID: 32999023 [TBL] [Abstract][Full Text] [Related]
20. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV. Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]